The two companies have been working together since 2017, with Takeda pledging $100 million to help GammaDelta advance its cell therapy platform as part of a "build-to-buy" arrangement. The ...
Allogeneic stem cell therapy allows "off the shelf" cells ... In the likely event of an EU licence for the therapy, Takeda will pay a 15 million euro fee to Tigenix. Apart from affecting the ...
Hosted on MSN1mon
Takeda licensed for anaemia therapy by Keros TherapeuticsTakeda has agreed to receive an exclusive global licence from Keros Therapeutics to advance the development, manufacture and commercialisation of the investigational activin inhibitor elritercept ...
Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. | “There's an evolution of our economic model that starts with IRA, and will get worse and ...
Former CRISPR (NASDAQ:CRSP) Chief Medical Officer Dr. Phuong Khanh Morrow, who resigned just days after the company won FDA approval for its landmark gene therapy Casgevy, has moved to Takeda ...
Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda said it's laser-focused on six pipeline assets that could each reel in ...
Global Cell Therapy market is driven by increasing demand for advanced therapies in oncology, regenerative medicine, and immunology. The market's expansion is also fueled by continuous innovations in ...
Inc., Takeda Pharmaceutical Company Ltd, Smith & Nephew plc, Fujifilm Holding Corporation, NuVasive, Inc. The utilization of stem cell therapy is expected to witness a significant rise owing to the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback